We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · April 19, 2021

Early ctDNA Changes Predict Response to First-Line Pembrolizumab-Based Therapy in NSCLC

Journal for immunotherapy of cancer

 

Additional Info

Journal for immunotherapy of cancer
Early Plasma Circulating Tumor DNA (ctDNA) Changes Predict Response to First-Line Pembrolizumab-Based Therapy in Non-Small Cell Lung Cancer (NSCLC)
J Immunother Cancer 2021 Mar 01;9(3)e001504, B Ricciuti, G Jones, M Severgnini, JV Alessi, G Recondo, M Lawrence, T Forshew, C Lydon, M Nishino, M Cheng, M Awad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading